Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03561584
Other study ID # 2018P000019
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date July 1, 2018
Est. completion date November 1, 2024

Study information

Verified date December 2023
Source Brigham and Women's Hospital
Contact Charu Madhwani Jain, MD, MPH
Phone 617-732-9119
Email cmjain@bwh.harvard.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicenter, randomized, double-blinded placebo controlled trial to assess the benefit of sulfasalazine in the treatment of PSC. The specific objectives of this study are to determine if sulfasalazine treatment 1) results in reduced serum ALP and other biomarkers of liver injury in PSC; 2) improves PSC patient symptoms; and 3) is safe in patients with PSC. We are recruiting remotely throughout the United States so an individual anywhere in the US with PSC and IBD can be enrolled.


Description:

As there is a strong association between PSC and IBD, it is reasonable to hypothesize that a therapy of proven benefit for UC may prove to also be effective for PSC. Unfortunately, several therapies which are indicated for the treatment of UC have not been effective in PSC including anti-TNF therapies and other anti-inflammatory medications. Sulfasalazine and mesalamine, medications commonly used for the treatment of UC, may be exceptions to this trend. While this therapy has never been formally tested in PSC, some retrospective reports suggest a possible benefit. Our current understanding of the mechanism of action of these medications suggests there is reasonable to believe they may also be effective in PSC. We are recruiting remotely throughout the United States so an individual anywhere in the US with PSC and IBD can be enrolled.


Recruitment information / eligibility

Status Recruiting
Enrollment 42
Est. completion date November 1, 2024
Est. primary completion date September 1, 2024
Accepts healthy volunteers No
Gender All
Age group 15 Years to 80 Years
Eligibility Inclusion Criteria: 1. Age 15-80 2. A diagnosis of PSC for at least 6 months based upon cholangiography (ERCP or MRCP) demonstrating intrahepatic and/or extrahepatic biliary strictures, beading or irregularity consistent with PSC. 3. ALP > 1.67 times the upper limit of normal (ULN) at screening 4. Inflammatory bowel disease 5. Subject must either be on a stable dose of ursodeoxycholic acid for > 6 months prior to screening or have been discontinued > 4 weeks prior to screening (enrollment of patients who are on UDCA will be limited to 50% of all enrolled patients). We are recruiting remotely throughout the United States so an individual anywhere in the US with PSC and IBD can be enrolled. Exclusion Criteria: 1. Anticipated need for liver transplant within one year as determined by Mayo PSC risk score treatment 2. Evidence of decompensated liver disease such as variceal bleeding, ascites, or hepatic encephalopathy. 3. Evidence of advanced liver disease including MELD score > 10, bilirubin > 3.0, platelet count < 100,000; or INR > 1.4 4. Concomitant chronic liver disease including alcohol related liver disease, chronic hepatitis B or C infection, haemochromatosis, Wilson's disease, alpha1-antitrypsin deficiency, non-alcoholic steatohepatitis, autoimmune hepatitis, or primary biliary cholangitis 5. Secondary causes of sclerosing cholangitis 6. Known intolerance to sulfasalazine (including but not limited to allergy to sulfa or mesalamine) or folic acid 7. History of cholangiocarcinoma or colon cancer within 5 years 8. History of colectomy with > 1/3 bowel resected 9. Treatment with any investigational agents, within two months or 5 half-lives of the investigational product, whichever is longer. 10. Active illicit drug or alcohol abuse 11. Current or past use of sulfasalazine within 6 months of enrollment. 12. Need for chronic use of antibiotics 13. Evidence of bacterial cholangitis within 6 months of enrollment 14. In patients with Ulcerative Colitis, simple clinical colitis activity index of > 4 or, if Crohn's disease, a Harvey-Bradshaw index of > 5 15. Chronic kidney injury (eGFR < 59) 16. Pregnancy or lactation

Study Design


Intervention

Drug:
Sulfasalazine
Patients will be initiated on a low dose of sulfasalazine (500 mg) twice daily (bid). Dosage will be increased throughout the study.
Placebo
Patients will be initiated on 1 placebo tablet twice daily (bid). Dosage will be increased throughout the study.

Locations

Country Name City State
United States Brigham and Women's Hospital Chestnut Hill Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Brigham and Women's Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Reduction in Mean Alkaline Phosphatase (ALP) Proportion of patients with reduction of mean ALP < 1.5 x ULN at end of treatment Baseline through the end of the Study at Week 22
Primary Normalization of ALP below the upper limit of normal Assessment in number of patients whose ALP normalizes Baseline through the end of the Study at Week 22
Secondary Overall changes in ALP levels Proportion of patients with ALP > or < 1.5 x ULN at end of treatment Baseline through the end of the Study at Week 22
Secondary Changes in blood tests Change in mean Liver Function Tests (e.g. Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), total bilirubin) and C-reactive Protein Baseline through the end of the Study at Week 22
Secondary Adverse Events Unexpected and Serious Adverse Events will be examined Baseline through the end of the Study at Week 22
Secondary Changes in Mayo PSC risk score Number of patients with changes in Mayo PSC risk score Baseline through the end of the Study at Week 22
Secondary Changes in Modified Fatigue Scale (MFS) Number of patients with changes in MFS score Baseline through the end of the Study at Week 22
Secondary Changes in pruritus visual analog scale (VAS) Number of patients with changes in VAS score Baseline through the end of the Study at Week 22
See also
  Status Clinical Trial Phase
Completed NCT02239211 - A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis Phase 2
Withdrawn NCT03216876 - A Study Of Ursolic Acid For Primary Sclerosing Cholangitis Phase 1
Recruiting NCT02605213 - Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients Phase 4
Recruiting NCT01688024 - Mitomycin C Therapy for Patients With Primary Sclerosing Cholangitis Phase 2
Completed NCT03041662 - Surveillance Study for Early Detection of Cholangiocarcinoma (CCA) in Primary Sclerosing Cholangitis (PSC)
Completed NCT05866809 - Evaluation of the Safety and Efficacy of HK-660S in Patients With Primary Sclerosing Cholangitis Phase 2
Recruiting NCT05618145 - National Database on Primary Sclerosing Cholangitis (PSC)
Active, not recruiting NCT02446665 - Disease Status in Primary Sclerosing Cholangitis by Elastography N/A
Completed NCT02247934 - Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC) N/A
Completed NCT01088607 - Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis Phase 1
Terminated NCT01142323 - Pilot Study of Fenofibrate for PSC Phase 1/Phase 2
Terminated NCT04060147 - Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis Phase 1
Recruiting NCT04133792 - Effect of Simvastatin on the Prognosis of Primary Primary Sclerosing Cholangitis (PSC) Phase 3
Active, not recruiting NCT04595825 - CM-101 in PSC Patients -The SPRING Study Phase 2
Recruiting NCT03183570 - Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT Early Phase 1
Completed NCT02943460 - Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis Phase 2
Completed NCT00951327 - Cholangioscopy Using Narrow Band Imaging (NBI) in Patients With Primary Sclerosing Cholangitis (PSC) Undergoing Endoscopic Retrograde Cholangiopancreatogram (ERCP) N/A
Completed NCT04024813 - A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC Phase 2
Recruiting NCT05912387 - Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study Early Phase 1
Completed NCT02884557 - NKT Role in the Regulation of the Inflammatory Bowel Disease N/A